Table.

Baseline characteristics of those in the Karonga Prevention Trial, overall and among those with follow-up information in the two areas

	Total vaccinated		Northern follow-up population		Southern follow-up population
	Received BCG (n=23 528)	Received placebo (n=23 361)	Received BCG (n=3709)	Received placebo (n=3612)	Received BCG (n=2449)	Received placebo (n=2413)
Age at vaccination, years
<5	3598 (15·3%)	3542 (15·2%)	610 (16·5%)	604 (16·7%)	269 (11·0%)	249 (10·3%)
5–14	9692 (41·2%)	9704 (41·5%)	1521 (41·0%)	1516 (42·0%)	1043 (42·6%)	1030 (42·7%)
15–24	5911 (25·1%)	5926 (25·4%)	830 (22·4%)	822 (22·8%)	705 (28·8%)	684 (28·4%)
25–75	4327 (18·4%)	4189 (17·9%)	748 (20·2%)	670 (18·6%)	432 (17·6%)	450 (18·7%)
Sex
Male	11 670 (49·6%)	11 545 (49·4%)	1859 (50·1%)	1833 (50·8%)	1199 (49·0%)	1191 (49·4%)
Female	11 858 (50·4%)	11 816 (50·6%)	1850 (49·9%)	1779 (49·3%)	1250 (51·0%)	1222 (50·6%)